Treating agent for irritable bowel syndrome
AssigneeAstellas Pharma Inc.
InventorsAkito Nishida, Akira Niwa, Yutaka Atsuta
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.
Claims15
A pharmaceutical composition comprising 0.002 to 0.02 mg of ramosetron hydrochloride or an equivalent molar amount of ramosetron or other pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising 0.0025 to 0.02 mg of ramosetron or an equivalent molar amount of a pharmaceutically acceptable salt of ramosetron.
A pharmaceutical composition adapted for administration to a human comprising 0.002 to 0.02 mg of ramosetron hydrochloride or an equivalent molar amount of ramosetron or other pharmaceutically acceptable salt thereof.
A pharmaceutical composition adapted for administration to a human comprising 0.0025 to 0.02 mg of ramosetron or an equivalent molar amount of a pharmaceutically acceptable salt of ramosetron.
Dependencies are inferred from the claim text.